NCT05019703 2026-04-17
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
9 trialsNCT05691478 2026-04-15
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT02243605 2026-04-13
Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02867592 2026-04-13
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06341712 2026-03-31
CabOSTar
Ipsen
Phase 2 Terminated
NCT06156410 2025-11-14
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Children's Hospital of Philadelphia
Phase 1 Recruiting
NCT05182164 2025-10-07
PEMBROCABOSARC
Institut Bergonié
Phase 2 Recruiting
NCT05135975 2025-08-12
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Nationwide Children's Hospital
Phase 2 Recruiting
NCT04661852 2023-02-15
Cabozantinib With Topotecan-Cyclophosphamide
Dana-Farber Cancer Institute
Phase 1 Completed